ORGO
Organogenesis Holdings Inc
NASDAQ · Biotechnology
$3.77
+0.06 (+1.62%)
Open$3.80
Previous Close$3.71
Day High$3.86
Day Low$3.73
52W High$7.08
52W Low$2.61
Volume—
Avg Volume572.3K
Market Cap478.46M
P/E Ratio476.08
EPS$0.00
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+121.5% upside
Current
$3.77
$3.77
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 464.61M | 460.10M | 178.18M |
| Net Income | 824.9K | 735.2K | 16.02M |
| Profit Margin | 0.2% | 0.2% | 9.0% |
| EBITDA | 11.92M | 11.21M | 21.94M |
| Free Cash Flow | — | — | 12.41M |
| Rev Growth | +1.0% | +1.0% | +15.4% |
| Debt/Equity | 0.00 | 0.00 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |